In addition, with CMU-C patients do not have to pay ""up-front", which is the common rule in France. Low-income patients and recipients of social benefits have reduced co-payments on pharmaceuticals. The government subsidises so-called Very-Low-Cost-Access (VLCA) practices, which typically serve disadvantaged areas under the condition that they forgo revenue from patient fees.